SAB Biotherapeutics (NASDAQ:SABS) Trading Down 6.6% – Here’s What Happened

SAB Biotherapeutics, Inc. (NASDAQ:SABS) shares dropped 6.6% during mid-day trading on Friday . The stock traded as low as $3.82 and last traded at $3.85. Approximately 274,534 shares traded hands during trading, a decline of 31% from the average daily volume of 396,190 shares. The stock had previously closed at $4.12.

Wall Street Analyst Weigh In

SABS has been the subject of a number of research reports. Weiss Ratings reissued a “sell (d)” rating on shares of SAB Biotherapeutics in a research note on Monday, December 29th. Chardan Capital reiterated a “buy” rating and set a $12.00 price objective on shares of SAB Biotherapeutics in a research note on Thursday, December 18th. UBS Group started coverage on SAB Biotherapeutics in a research report on Wednesday, January 7th. They issued a “buy” rating and a $7.00 target price on the stock. Guggenheim assumed coverage on SAB Biotherapeutics in a research report on Friday, December 19th. They set a “buy” rating and a $15.00 price target for the company. Finally, Wall Street Zen upgraded SAB Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $10.00.

SAB Biotherapeutics Stock Down 6.6%

The company has a quick ratio of 10.50, a current ratio of 10.49 and a debt-to-equity ratio of 0.02. The firm has a market cap of $183.30 million, a price-to-earnings ratio of -1.25 and a beta of 0.59. The firm has a fifty day moving average price of $3.96 and a 200-day moving average price of $3.12.

SAB Biotherapeutics (NASDAQ:SABS) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.38. As a group, sell-side analysts forecast that SAB Biotherapeutics, Inc. will post -3.69 EPS for the current year.

Hedge Funds Weigh In On SAB Biotherapeutics

Large investors have recently bought and sold shares of the company. State of Wyoming bought a new stake in shares of SAB Biotherapeutics in the fourth quarter worth $34,000. State Street Corp acquired a new position in shares of SAB Biotherapeutics during the 4th quarter worth about $49,000. ADAR1 Capital Management LLC bought a new position in shares of SAB Biotherapeutics in the 3rd quarter valued at about $30,000. Dimensional Fund Advisors LP acquired a new stake in shares of SAB Biotherapeutics in the third quarter valued at about $32,000. Finally, Virtu Financial LLC bought a new stake in SAB Biotherapeutics during the third quarter worth about $40,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.